MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo.
Saved in:
| Title: | MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo. |
|---|---|
| Authors: | Saporito MS; Melior Discovery, Inc., 860 Springdale Drive, Exton, PA 19341, USA. msaporito@meliordiscovery.com, Ochman AR, Lipinski CA, Handler JA, Reaume AG |
| Source: | The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2012 Jul; Vol. 342 (1), pp. 15-22. Date of Electronic Publication: 2012 Apr 03. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
